Researchers at Austin Health in Australia are recruiting Alzheimer's disease patients at the end stages of their lives to participate in a study that will compare MRI and PET scan images of their brains while they are alive to brain samples collected upon their death. The researchers seek to determine whether the levels of amyloid shown in the scans will correlate with those seen in brain samples after death.
HHS' tiger team on Tuesday considered ways to enable patients to decide whether to allow data access when it involves their sensitive health information. The panel proposed developing models to test whether giving patients control over their consent preferences is feasible. "We want to honor patient preferences from the policy perspective and determine if technology supports it," the panel's chairman said.
The European Commission has presented to the European Parliament a plan aimed at securing the longevity and supply levels for necessary materials for radiology, radiotherapy and nuclear medicine in the region. Among the goals of the commission's six-point plan are to update the Directive 97/43/Euratom in order to bolster the regulatory framework and promote radiation protection, while also analyzing financing opportunities to maintain a proper supply of radioisotopes.
Belgian researchers who monitored the levels of beta amyloid and tau -- two proteins linked to Alzheimer's disease -- in spinal fluid said the technique helped accurately identify Alzheimer's in 90% of patients with the disease. The method also pinpointed all of the study participants with memory problems who would go on to develop the disease in the next five years.
RadNet, an operator of medical diagnostic imaging centers, said its fourth-quarter profit was driven by an increase in imaging volume and reduced expenses. The company's overall imaging exam volume increased 3%, and PET/CT volume increased 5.1%.